The Private Water Supplies (Wales) (Amendment) Regulations 2016 (revoked)
W.S.I. 2016/411 · Made 21 March 2016 · Extends to England and Wales
Water, Wales
Made 21 March 2016
Laid before the National Assembly for Wales 23 March 2016
Coming into force 14 April 2016
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Annotations to the whole text
Textual amendments
- F1
Regulations revoked (20.11.2017) by The Private Water Supplies (Wales) Regulations 2017 (S.I. 2017/1041), reg. 24(1)(d) (with reg. 3)
Contents
- 1Title, commencement and interpretation Repealed
- 2Amendment of regulation 10 (other private supplies) Repealed
- 3New regulations 10A (monitoring of radioactive substances: general) and 10B (monitoring of radioactive substances: supplies to a single dwelling not used for a commercial or public activity) Repealed
- 4Amendment of Table C (prescribed concentrations, values or states) in Part 2 of Schedule 1 Repealed
- 5Insertion of new Part 3 (radioactive substances parameters) of Schedule 1 Repealed
- 6Amendment of Part 2 of Schedule 2 Repealed
- 7Insertion of new Schedule 2A (monitoring of radioactive substances) Repealed
- 8Insertion of new Part 3 of Schedule 3 (monitoring for indicative dose and analytical performance characteristics) Repealed
- Signature
- Schedule 1Schedule 1 Repealed
- Schedule 2Schedule 2 Repealed
- Schedule 3Schedule 3 Repealed
- Explanatory note
1Title, commencement and interpretationF1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2Amendment of regulation 10 (other private supplies)F1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3New regulations 10A (monitoring of radioactive substances: general) and 10B (monitoring of radioactive substances: supplies to a single dwelling not used for a commercial or public activity)F1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4Amendment of Table C (prescribed concentrations, values or states) in Part 2 of Schedule 1F1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5Insertion of new Part 3 (radioactive substances parameters) of Schedule 1F1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6Amendment of Part 2 of Schedule 2F1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7Insertion of new Schedule 2A (monitoring of radioactive substances)F1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8Insertion of new Part 3 of Schedule 3 (monitoring for indicative dose and analytical performance characteristics)F1
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Signature
F1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Schedule 1F1
“PART 3
Radioactive substances parameters
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”
Schedule 2F1
“SCHEDULE 2A
Monitoring of radioactive substances
Regulation 10A
Radon
1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tritium
2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Indicative Dose
3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Water treatment
4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Averaging
5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”
Schedule 3F1
“PART 3
Monitoring for indicative dose and analytical performance characteristics
Monitoring for compliance with the indicative dose
5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Screening for certain radionuclides, or screening for an individual radionuclide
7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Screening strategies for gross alpha activity and gross beta activity
9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Calculation of the indicative dose
12. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Performance characteristics and methods of analysis
14. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”
Explanatory note
F1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .